Skip to main content
NCBI home page
British Medical Journal logoLink to British Medical Journal
. 1975 Jun 28;2(5973):711–713. doi: 10.1136/bmj.2.5973.711

Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an E.O.R.T.C. study.

J C Heuson, E Engelsman, J Blonk-Van Der Wijst, H Maass, A Drochmans, J Michel, H Nowakowski, A Gorins
PMCID: PMC1673940  PMID: 1095121

Abstract

A randomized clinical trial of nafoxidine, a non-steroidal oestrogen antagonist, and ethinyloestradiol in postmenopausal patients with advanced breast cancer produced objective remissions in 31% of 49 women receiving nafoxidine and in 14% of 49 receiving ethinyloestradiol. The differences in remission rates was almost significant (0.05 less than P less than 0.10). Life-threatening complications were more frequent with ethinyloestradiol than with nafoxidine but the latter produced specific toxic reactions on skin and hair that may limit its practical usefulness. Synthetic oestrogen antagonists may occupy a privileged place in the treatment of breast cancer, and other representatives of this new class of compounds should be accurately assessed in randomized clinical trials.

Full text

PDF
711

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clark J. H., Anderson J. N., Peck E. J., Jr Estrogen receptor-anti-estrogen complex: atypical binding by uterine nuclei and effects on uterine growth. Steroids. 1973 Nov;22(5):707–718. doi: 10.1016/0039-128x(73)90118-9. [DOI] [PubMed] [Google Scholar]
  2. Cole M. P., Jones C. T., Todd I. D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971 Jun;25(2):270–275. doi: 10.1038/bjc.1971.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Heuson J. C., Waelbroeck C., Legros N., Gallez G., Robyn C., L'Hermite M. Inhibition of DMBA-induced mammary carcinogenesis in the rat by 2-br- -ergocryptine (CB 154), an inhibitor of prolactin secretion, and by nafoxidine (U-11, 100 A), an estrogen antagonist. Gynecol Invest. 1971;2(1):130–137. doi: 10.1159/000301858. [DOI] [PubMed] [Google Scholar]
  4. Jensen E. V., DeSombre E. R. Mechanism of action of the female sex hormones. Annu Rev Biochem. 1972;41:203–230. doi: 10.1146/annurev.bi.41.070172.001223. [DOI] [PubMed] [Google Scholar]
  5. McGuire W. L., Chamness G. C., Costlow M. E., Shepherd R. E. Hormone dependence in breast cancer. Metabolism. 1974 Jan;23(1):75–100. doi: 10.1016/0026-0495(74)90106-1. [DOI] [PubMed] [Google Scholar]
  6. Rochefort H., Lignon F., Capony F. Formation of estrogen nuclear receptor in uterus: effect of androgens, estrone and nafoxidine. Biochem Biophys Res Commun. 1972 May 26;47(4):662–670. doi: 10.1016/0006-291x(72)90543-8. [DOI] [PubMed] [Google Scholar]
  7. Ruh T. S., Ruh M. F. The effect of antiestrogens on the nuclear binding of the estrogen receptor. Steroids. 1974 Aug;24(2):209–224. doi: 10.1016/0039-128x(74)90104-4. [DOI] [PubMed] [Google Scholar]
  8. Terenius L. Anti-oestrogens and breast cancer. Eur J Cancer. 1971 Feb;7(1):57–64. doi: 10.1016/0014-2964(71)90095-8. [DOI] [PubMed] [Google Scholar]
  9. Terenius L. Structure-activity relationships of anti-oestrogens with regard to interaction with 17-beta-oestradiol in the mouse uterus and vagina. Acta Endocrinol (Copenh) 1971 Mar;66(3):431–447. doi: 10.1530/acta.0.0660431. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES